Small Pharma’s Big Minds – Alex Kelly
Find out more about the big minds behind the team at Small Pharma through conversations with the people who work here.
Small Pharma’s Senior Clinical Operations Manager Alex Kelly shares more about his role, and why he believes in the importance of prioritizing mental health funding in the same way as physical health – on a global scale.
Who you are and what you do
I’m Alex Kelly, the Senior Clinical Operations Manager here at Small Pharma and I was brought in to head up and oversee the Phase IIb trial. In clinical trials we look for very specific types of patients and so we can’t just work locally in the UK; we have to go to multiple countries to find those patients, we wouldn’t be able to do the Phase IIb trial in the UK alone. We are going to be focusing on North America and Europe.
What excites you most about Small Pharma?
I’m excited personally because I want to be working on a compound where there is huge unmet need. I get motivation from working ultimately on something that can have impact on people’s lives at a global level.
What does good mental health mean to you?
I feel that mental health is underserved in this country and other countries around the world. Physical health is always given the priority, it’s given more funding. However mental health is just as important as physical health for overall health. On a personal level I’ve been impacted, and seen people with severe depression, and this is something people don’t really realise has a huge impact on someone’s overall ability to function. It motivates me working at Small Pharma because we’re working on something that hopefully will serve a huge unmet need.
Alex Kelly joined the team at Small Pharma in 2022. He brings with him over 20 years’ experience in pharmaceutical development, including his work to bring the first licensed cannabinoid medication to the US market.